Vanguard Personalized Indexing Management LLC Has $199,000 Holdings in Sotera Health Company $SHC

Vanguard Personalized Indexing Management LLC grew its stake in shares of Sotera Health Company (NASDAQ:SHC) by 38.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,878 shares of the company’s stock after acquiring an additional 4,951 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Sotera Health were worth $199,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of SHC. New York State Teachers Retirement System lifted its position in Sotera Health by 1.9% during the first quarter. New York State Teachers Retirement System now owns 59,273 shares of the company’s stock worth $691,000 after acquiring an additional 1,100 shares during the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Sotera Health in the first quarter valued at approximately $266,000. Principal Financial Group Inc. raised its position in shares of Sotera Health by 0.3% in the first quarter. Principal Financial Group Inc. now owns 352,388 shares of the company’s stock valued at $4,109,000 after buying an additional 1,037 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Sotera Health by 5.7% in the first quarter. Victory Capital Management Inc. now owns 57,655 shares of the company’s stock valued at $672,000 after buying an additional 3,106 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Sotera Health in the first quarter valued at approximately $602,000. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Sotera Health Stock Performance

NASDAQ SHC opened at $16.86 on Friday. The firm’s fifty day moving average price is $16.09 and its two-hundred day moving average price is $13.37. The stock has a market cap of $4.79 billion, a PE ratio of 210.78 and a beta of 1.82. Sotera Health Company has a fifty-two week low of $9.53 and a fifty-two week high of $17.15. The company has a debt-to-equity ratio of 4.49, a quick ratio of 2.23 and a current ratio of 2.47.

Sotera Health (NASDAQ:SHC) last posted its earnings results on Friday, August 8th. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.17 by $0.03. The firm had revenue of $294.34 million for the quarter, compared to analysts’ expectations of $275.81 million. Sotera Health had a net margin of 2.14% and a return on equity of 39.42%. The company’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.19 earnings per share. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. On average, equities analysts expect that Sotera Health Company will post 0.61 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Michael P. Rutz sold 126,611 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $16.38, for a total value of $2,073,888.18. Following the sale, the insider owned 450,204 shares of the company’s stock, valued at $7,374,341.52. The trade was a 21.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gtcr Investment Xi Llc sold 8,000,000 shares of the business’s stock in a transaction on Friday, September 5th. The stock was sold at an average price of $15.11, for a total transaction of $120,880,000.00. Following the completion of the sale, the director directly owned 41,215,301 shares in the company, valued at approximately $622,763,198.11. This represents a 16.26% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 20,126,611 shares of company stock valued at $304,273,888. 47.55% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Sotera Health in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Sotera Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Finally, Barclays lifted their price target on shares of Sotera Health from $17.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.20.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.